EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50% - Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; ÖZGÜROĞLU, Mustafa; Gogishvili, M.; TÜRK, HACI MEHMET; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; et al. (2020)